Fig. 7From: High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancerProgression-free survival according to PRTN3 expression in the anti-VEGF antibody treatment subgroups. (a) Progression-free survival of patients treated with bevacizumab. (b) Progression-free survival of patients treated without bevacizumab. *P<0.05Back to article page